PCSK9
A gene target in base editing trials for hypercholesterolemia. Humans with natural null mutations for PCSK9 are healthy, indicating its safety and effectiveness as a therapeutic target.
Save the 5 videos on PCSK9 to your own pod.
Sign up free to keep building your knowledge base on PCSK9 as more episodes are added.
Videos Mentioning PCSK9
George Church, PhD: Rewriting Genomes to Eradicate Disease and Aging
FoundMyFitness
A gene target in base editing trials for hypercholesterolemia. Humans with natural null mutations for PCSK9 are healthy, indicating its safety and effectiveness as a therapeutic target.
AMA #3: supplements, women’s health, patient care, and more (EP.26) | The Peter Attia Drive
Peter Attia MD
Proprotein convertase subtilisin/kexin type 9, an enzyme that degrades LDL receptors; berberine is a weak inhibitor of this enzyme.
The impact of body fat on metabolic health | Peter Attia & Ethan Weiss
Peter Attia MD
210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.
Peter Attia MD
Proprotein convertase subtilisin kexin type 9, discovered in 2003, acts as a regulator of the LDL receptor, preventing its recycling and leading to higher LDL levels.
#19 – Dave Feldman: stress testing the lipid energy model
Peter Attia MD
A protein that regulates LDL receptor degradation. Hyper-functioning PCSK9 leads to fewer LDL receptors and higher LDL levels, while hypo-functioning PCSK9 leads to more LDL receptors and lower LDL levels.